S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.47 (+1.28%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.47 (+1.28%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.47 (+1.28%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
S&P 500   3,358.63 (+0.69%)
DOW   27,733.73 (+1.02%)
QQQ   279.47 (+1.28%)
AAPL   116.33 (+1.96%)
MSFT   210.41 (+1.52%)
FB   262.89 (+0.42%)
GOOGL   1,475.66 (+0.66%)
AMZN   3,168.06 (+0.74%)
TSLA   428.81 (+2.32%)
NVDA   542.06 (+2.46%)
BABA   291.91 (+5.41%)
CGC   14.37 (-0.90%)
GE   6.23 (+1.80%)
MU   47.52 (-6.29%)
AMD   82.59 (+1.00%)
T   28.46 (+0.57%)
F   6.64 (+0.61%)
ACB   4.66 (-0.43%)
GILD   62.97 (+1.40%)
NFLX   501.02 (+1.53%)
DIS   124.37 (-0.82%)
BA   166.66 (+1.87%)
BAC   24.06 (+1.22%)
Log in
NASDAQ:MCRB

Seres Therapeutics News Headlines

$28.54
-0.20 (-0.70 %)
(As of 09/30/2020 02:40 PM ET)
Add
Compare
Today's Range
$28.18
Now: $28.54
$29.22
50-Day Range
$20.04
MA: $25.09
$27.33
52-Week Range
$2.52
Now: $28.54
$33.00
Volume19,979 shs
Average Volume1.25 million shs
Market Capitalization$2.18 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.5

Headlines

Seres Therapeutics (NASDAQ MCRB) News Headlines Today

Source:
DateHeadline
Seres Therapeutics (NASDAQ:MCRB) Price Target Increased to $42.00 by Analysts at Canaccord GenuitySeres Therapeutics (NASDAQ:MCRB) Price Target Increased to $42.00 by Analysts at Canaccord Genuity
marketbeat.com - September 21 at 7:42 AM
Seres Therapeutics (NASDAQ:MCRB) Earns Overweight Rating from Analysts at Piper SandlerSeres Therapeutics (NASDAQ:MCRB) Earns Overweight Rating from Analysts at Piper Sandler
marketbeat.com - August 18 at 7:15 AM
Seres Therapeutics (NASDAQ:MCRB) Stock Price Up 7.3%Seres Therapeutics (NASDAQ:MCRB) Stock Price Up 7.3%
americanbankingnews.com - September 29 at 7:02 PM
Analyzing Seres Therapeutics (NASDAQ:MCRB) and Catalyst Biosciences (NASDAQ:CBIO)Analyzing Seres Therapeutics (NASDAQ:MCRB) and Catalyst Biosciences (NASDAQ:CBIO)
americanbankingnews.com - September 22 at 7:37 PM
Seres Therapeutics (NASDAQ:MCRB) PT Raised to $42.00 at Canaccord GenuitySeres Therapeutics (NASDAQ:MCRB) PT Raised to $42.00 at Canaccord Genuity
americanbankingnews.com - September 21 at 8:36 AM
Chardan downgrades Seres Therapeutics to NeutralChardan downgrades Seres Therapeutics to Neutral
seekingalpha.com - September 18 at 7:32 PM
Chardan Capital Downgrades Seres Therapeutics (NASDAQ:MCRB) to NeutralChardan Capital Downgrades Seres Therapeutics (NASDAQ:MCRB) to Neutral
americanbankingnews.com - September 18 at 10:48 AM
Analyzing BELLUS Health (NASDAQ:BLU) & Seres Therapeutics (NASDAQ:MCRB)Analyzing BELLUS Health (NASDAQ:BLU) & Seres Therapeutics (NASDAQ:MCRB)
americanbankingnews.com - September 18 at 9:18 AM
Microbiome startup raises $90M as it prepares for a potential FDA firstMicrobiome startup raises $90M as it prepares for a potential FDA first
bizjournals.com - September 17 at 8:27 AM
Seres Therapeutics (NASDAQ:MCRB) Trading 5.9% Higher Seres Therapeutics (NASDAQ:MCRB) Trading 5.9% Higher
americanbankingnews.com - September 14 at 9:50 PM
Seres Therapeutics to Present at Upcoming Investor ConferencesSeres Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 14 at 7:36 AM
Seres Therapeutics (NASDAQ:MCRB) Earns Buy Rating from OppenheimerSeres Therapeutics (NASDAQ:MCRB) Earns Buy Rating from Oppenheimer
americanbankingnews.com - September 14 at 6:16 AM
Contrasting Seres Therapeutics (NASDAQ:MCRB) and Adamis Pharmaceuticals (NASDAQ:ADMP)Contrasting Seres Therapeutics (NASDAQ:MCRB) and Adamis Pharmaceuticals (NASDAQ:ADMP)
americanbankingnews.com - September 11 at 1:39 PM
Seres Therapeutics receives FDA feedback for SER-109 marketing applicationSeres Therapeutics receives FDA feedback for SER-109 marketing application
seekingalpha.com - September 11 at 8:15 AM
Seres Therapeutics closing in on U.S. application for C. diff candidate SER-109Seres Therapeutics closing in on U.S. application for C. diff candidate SER-109
seekingalpha.com - September 11 at 8:15 AM
Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study ResultsSeres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
finance.yahoo.com - September 11 at 8:15 AM
The Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many ShareholdersThe Seres Therapeutics (NASDAQ:MCRB) Share Price Has Soared 590%, Delighting Many Shareholders
finance.yahoo.com - August 21 at 3:09 PM
Will Seres Therapeutics Incs price keep rising?Will Seres Therapeutics Inc's price keep rising?
uk.finance.yahoo.com - August 14 at 2:37 PM
Why Seres Therapeutics Stock Surged TodayWhy Seres Therapeutics Stock Surged Today
finance.yahoo.com - August 13 at 6:44 PM
Seres Therapeutics prices equity offering at $21.50Seres Therapeutics prices equity offering at $21.50
seekingalpha.com - August 13 at 8:43 AM
Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common StockSeres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
finance.yahoo.com - August 13 at 12:04 AM
Seres Therapeutics Reaches Analyst Target PriceSeres Therapeutics Reaches Analyst Target Price
nasdaq.com - August 11 at 5:57 PM
Seres Therapeutics Stock Scales Nasdaq on Positive Drug DataSeres Therapeutics Stock Scales Nasdaq on Positive Drug Data
finance.yahoo.com - August 10 at 6:37 PM
Why Seres Therapeutics Stock Skyrocketed 350% TodayWhy Seres Therapeutics Stock Skyrocketed 350% Today
finance.yahoo.com - August 10 at 6:37 PM
Good News for C Diff Sufferers and Seres Therapeutics InvestorsGood News for C Diff Sufferers and Seres Therapeutics Investors
msn.com - August 10 at 1:31 PM
Seres stock jumps 400% on microbiome trial successSeres stock jumps 400% on microbiome trial success
bizjournals.com - August 10 at 1:31 PM
Stock Alert: Seres Therapeutics Soars 300% On Positive Data From Trial Of Colon Infection DrugStock Alert: Seres Therapeutics Soars 300% On Positive Data From Trial Of Colon Infection Drug
nasdaq.com - August 10 at 1:31 PM
Return On Capital Employed Overview: Seres TherapeuticsReturn On Capital Employed Overview: Seres Therapeutics
benzinga.com - August 10 at 1:31 PM
Seres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome TherapeuticSeres Therapeutics Skyrockets On Positive Pivotal Study Results For Microbiome Therapeutic
msn.com - August 10 at 1:31 PM
This Tiny Biotech's Shares Quadruple After Late-Stage Drug Tests SucceedThis Tiny Biotech's Shares Quadruple After Late-Stage Drug Tests Succeed
finance.yahoo.com - August 10 at 1:31 PM
Seres Therapeutics up big on success of lead drug in C. diff studySeres Therapeutics up big on success of lead drug in C. diff study
seekingalpha.com - August 10 at 8:31 AM
Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile InfectionSeres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
finance.yahoo.com - August 10 at 8:31 AM
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Dont?Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
nasdaq.com - August 7 at 1:35 PM
Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?Do Options Traders Know Something About Seres Therapeutics (MCRB) Stock We Don't?
finance.yahoo.com - August 7 at 1:35 PM
Recap: Seres Therapeutics Q2 EarningsRecap: Seres Therapeutics Q2 Earnings
finance.yahoo.com - July 28 at 1:36 PM
Earnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to DeclineEarnings Preview: Seres Therapeutics (MCRB) Q2 Earnings Expected to Decline
finance.yahoo.com - July 28 at 1:36 PM
Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business UpdatesSeres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
finance.yahoo.com - July 28 at 8:35 AM
Flagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene WritingFlagship Pioneering's Scientists Invent a New Category of Genome Engineering Technology: Gene Writing
finance.yahoo.com - July 7 at 8:19 AM
Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy OfficerSeres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
finance.yahoo.com - June 22 at 10:25 AM
The pandemic upended clinical trials. Biotechs are now restarting them.The pandemic upended clinical trials. Biotechs are now restarting them.
www.bizjournals.com - June 5 at 1:00 PM
Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare ConferenceSeres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference
finance.yahoo.com - June 2 at 7:37 PM
Implied Volatility Surging for Seres Therapeutics (MCRB) Stock OptionsImplied Volatility Surging for Seres Therapeutics (MCRB) Stock Options
finance.yahoo.com - June 2 at 9:21 AM
Hedge Funds Have Never Been Less Bullish On Seres Therapeutics Inc (MCRB)Hedge Funds Have Never Been Less Bullish On Seres Therapeutics Inc (MCRB)
finance.yahoo.com - June 1 at 12:05 AM
Seres Therapeutics to Present at Jefferies Virtual Healthcare ConferenceSeres Therapeutics to Present at Jefferies Virtual Healthcare Conference
finance.yahoo.com - May 28 at 8:49 AM
Seres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-OutSeres Therapeutics to Host Virtual SER-109 Focused Symposium on May 27, 2020, Ahead of Phase 3 ECOSPOR III Study Read-Out
finance.yahoo.com - May 18 at 10:01 AM
Seres Therapeutics Reports Weak Earnings, But Significant Upside Lies AheadSeres Therapeutics Reports Weak Earnings, But Significant Upside Lies Ahead
finance.yahoo.com - May 11 at 4:37 AM
Seres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2020 Results - Earnings Call TranscriptSeres Therapeutics, Inc. (MCRB) CEO Eric Shaff on Q1 2020 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 6:42 AM
Seres Therapeutics Inc (MCRB) Q1 2020 Earnings Call TranscriptSeres Therapeutics Inc (MCRB) Q1 2020 Earnings Call Transcript
www.fool.com - May 9 at 1:34 PM
Edited Transcript of MCRB earnings conference call or presentation 7-May-20 12:30pm GMTEdited Transcript of MCRB earnings conference call or presentation 7-May-20 12:30pm GMT
finance.yahoo.com - May 8 at 6:31 PM
Seres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue EstimatesSeres Therapeutics (MCRB) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 7 at 1:09 PM
Seres Therapeutics EPS misses by $0.02, misses on revenueSeres Therapeutics EPS misses by $0.02, misses on revenue
seekingalpha.com - May 7 at 8:08 AM
Seres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business UpdatesSeres Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
finance.yahoo.com - May 7 at 8:08 AM
This page was last updated on 9/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.